Advertisement

Antineoplastic Drugs

  • Wolfgang Sadée
  • Yousry Mahmoud El Sayed
Protocol
  • 361 Downloads
Part of the Biological Methods book series (BM)

Abstract

The limited scope of therapeutic drug-level monitoring in cancer chemotherapy results from the often complex biochemical mechanisms that contribute to antineoplastic activity and obscure the relationships among drug serum levels and therapeutic benefits. Moreover, new agents for cancer chemotherapy are being introduced at a more rapid rate than for the treatment of other diseases, although the successful application of therapeutic drug-level monitoring may require several years of intensive study of the significance of serum drug levels. However, drug level monitoring can be of considerable value during phase I clinical trials of new antineoplastic agents in order to assess drug metabolism, bioavailability, and intersubject variability; these are important parameters in the interpretation of clinical studies, but have no immediate benefit to the patient. High performance liquid chromatography (HPLC) probably represents the most versatile and easily adaptable analytical technique for drug metabolite screening (1). HPLC may therefore now be the method of choice during phase I clinical trials of antineoplastic drugs. For example, within a single week we developed an HPLC assay—using a C18 reverse-phase column, UV detection, and direct serum injection after protein precipitation—for the new radiosensitizer, misonidazole (2).

Keywords

High Performance Liquid Chromatography Antineoplastic Agent Dihydrofolate Reductase Drug Serum Level Tetrabutyl Ammonium Hydroxide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Sadée, W., and Beelen, G. C. M., Drug Level Monitoring, Wiley, New York, 1980.Google Scholar
  2. 2.
    Marques, R. A., Stafford, B., Flynn, N., and Sadée, W., J. Chromatogr. 146, 163 (1978).Google Scholar
  3. 3.
    Wasserman, T. H., Philips, T. L., Johnson, R. L., Gomer, C. J., Lawrence, G. A., Sadée, W., and Marques, R. A., Int. J. Rad. Oncol. Biol. Phys. 5, 775 (1979).CrossRefGoogle Scholar
  4. 4.
    Sadée, W., Therap. Drug Monitor., in press.Google Scholar
  5. 5.
    Bleyer, W. A., Cancer Treat. Rev. 4, 87 (1977).CrossRefGoogle Scholar
  6. 6.
    Tattersall, M. H. N., Parker, L. M., Pitman, S. W., and Frei, E. III, Cancer Chemother. Rep. (Part 3) 6, 25 (1975).Google Scholar
  7. 7.
    Stoller, R. G., Hande, K. R., Jacobs, S. A., Rosenberg, S. A., and Chabner, B. A., N.E.J. Med. 297, 630 (1977).CrossRefGoogle Scholar
  8. 8.
    Frei, E. III, Jaffe, N., Tattersall, M. H. N., Pitman, S., and Parker, L., N.E.J. Med. 292, 846 (1975).CrossRefGoogle Scholar
  9. 9.
    Dedrick, R. L., Zaharko, D. S., and Lutz, R. J., J. Pharm. Sci. 62, 882 (1973).CrossRefGoogle Scholar
  10. 10.
    Goldman, D., Cancer Treat. Rep. (Part 3) 6, 51 (1975).Google Scholar
  11. 11.
    Canfell, C. and Sadée, W., Cancer Treat. Rep., in press (1980).Google Scholar
  12. 12.
    Watson, E., Cohen, J. L., and Chan, K. K., Cancer Treat. Rep. 62, 381 (1978).Google Scholar
  13. 13.
    Wisnicki, J. L., Tong, W. P., and Ludlum, D. B., Cancer Treat. Rep. 62, 529 (1978).Google Scholar
  14. 14.
    Lankelma, J., and Poppe, H., J. Chromatogr. 149, 587 (1978).CrossRefGoogle Scholar
  15. 15.
    Nelson, J. R., Harris, B. A., Decker, W. J., and Farquhar, D., Cancer Res. 37, 3970 (1977).Google Scholar
  16. 16.
    Cohen, J. L., and Brown, R. E., J. Chromatogr. 151, 237 (1978).CrossRefGoogle Scholar
  17. 17.
    Jones, R. A., Buckpitt, A. R., Londer, H. H., Myers, C. E., Chabner, B. A., and Boyd, M. R., Bull. Cancer 66, 75 (1979).Google Scholar
  18. 18.
    Au, J. L., Wu, A. T., Friedman, M. A., and Sadée, W., Cancer Treat. Rep. 63, 343 (1979).Google Scholar
  19. 19.
    Au, J. L., and Sadée, W., Cancer Res. 39, 4289 (1979).Google Scholar
  20. 20.
    Baurain, R., Deprez, D., De-Campeneere, and Trouet, A., Analyt. Biochem. 94, 112 (1979).CrossRefGoogle Scholar
  21. 21.
    Peters, J. H., and Murray, Jr., J. F., J. Liquid Chromatogr. 2, 45 (1979).CrossRefGoogle Scholar
  22. 22.
    Staffan, E., J. Chromatogr. 149, 225 (1978).CrossRefGoogle Scholar
  23. 23.
    Langone, J. J., and van Vunakis, H., Biochem. Med. 12, 283 (1975).CrossRefGoogle Scholar
  24. 24.
    Hulhoven, R., and Desager, J. P., J. Chromatogr. 125, 369 (1976).CrossRefGoogle Scholar
  25. 25.
    Shiu, G. K., Goehil, T. J., and Pitlick, W. H., J. Pharm. Sci. 68, 232 (1979).CrossRefGoogle Scholar
  26. 26.
    Terry, T. K., Belime, R. J., and Brooke, D., J. Pharm. Sci. 68, 172 (1979).CrossRefGoogle Scholar
  27. 27.
    Chang, S. Y., Alberts, D. S., Melvick, L. R., Walson, P. D., and Salman, S. E., J. Pharm. Sci. 5, 679 (1978A).CrossRefGoogle Scholar
  28. 28.
    Furner, R. L., Mellet, L. B., Brown, R. K., and Duncan, G., Drug Metab. Dispos. 4, 577 (1976).Google Scholar
  29. 29.
    Ding, T. L., and Benet, L. Z., J. Chromatogr. Biomed. Applic. 163, 281 (1979).CrossRefGoogle Scholar
  30. 30.
    Day, J. L., Tterlikkis, L., Niemann, R., Mobley, A., and Spikes, C., J. Pharm. Sci. 67, 1027 (1978).CrossRefGoogle Scholar
  31. 31.
    Weinkam, R. J., and Shiba, D. A., Life. Sci. 22, 937 (1978).CrossRefGoogle Scholar

Copyright information

© The Humana Press, Inc. 1981

Authors and Affiliations

  • Wolfgang Sadée
    • 1
  • Yousry Mahmoud El Sayed
    • 1
  1. 1.Departments of Pharmacy and Pharmaceutical Chemistry School of PharmacyUniversity of CaliforniaSan Francisco

Personalised recommendations